Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ASCO: Deintensified treatment in p16+ oropharyngeal cancer needs evaluation

Publish date:: May 2, 2019

Key clinical point: The hypothesis that deintensified treatment in patients with p16+ oropharyngeal cancer (OPC) can lower long-term adverse effects without impacting survival warrants further evaluation.

Major finding: Deintensified treatment for patients with p16+ OPC should occur only in the context of a clinical trial.

Study details: A provisional clinical opinion released by ASCO.

Disclosures: ASCO funded the study. The authors reported financial affiliations with AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, PDS Biotechnology, and several others.

Citation:

Adelstein DJ et al. J Clin Oncol. 2019 Apr 25. doi: 10.1200/JCO.19.00441.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Head & Neck/Thyroid Cancers

Immunotherapy could fill unmet need in leptomeningeal metastases,

New cancer drugs may have saved more than 1.2 million Americans,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,

Survey quantifies COVID-19’s impact on oncology,

VTE, sepsis risk increased among COVID-19 patients with cancer,